Vascular aspects of fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine

Hypertension

Volumn 60, Issue 4, 2012, Pages 998-1005

  Rombach, Saskia M ^a   Van Den Bogaard, Bas ^b   De Groot, Eric ^b   Groener, Johanna E M ^b   Poorthuis, Ben J ^b   Linthorst, Gabor E ^a   Van Den Born, Bert Jan H ^b   Hollak, Carla E M ^a   Aerts, Johannes M F G ^b  

^a Division of Endocrinology and Metabolism   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

advanced glycation end products; Fabry disease; flow mediated dilation; globotriaosylsphingosine; intima media thickness; pulse wave velocity

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AGALSIDASE ALFA; AGALSIDASE BETA; GLOBOTRIAOSYLSPHINGOSINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SPHINGOSINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; FLOW MEDIATED DILATION; HUMAN; HYPERTENSION; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE WAVE; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; AGED, 80 AND OVER; BLOOD FLOW VELOCITY; BRACHIAL ARTERY; CAROTID ARTERIES; CAROTID INTIMA-MEDIA THICKNESS; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; GLYCOLIPIDS; HUMANS; MALE; MIDDLE AGED; SPHINGOLIPIDS;

EID: 84866548541     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.112.195685     Document Type: Article

References (50)

1. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A defciency: Fabry disease. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001;3:3733-3774.
2. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249-254.
3. Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC, Yeh H Y, Chao MC, Lin SJ, Kitagawa T, Desnick RJ, Hsu LW. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c. 936+919G>A (IVS4+919G>A). Hum Mutat. 2009;30:1397-1405.
4. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79:31-40.
5. Schiffmann R, Rapkiewicz A, Abu-Asab M, Ries M, Askari H, Tsokos M, Quezado M. Pathological fndings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch. 2006;448:337-343.
6. Barbey F, Brakch N, Linhart A, Jeanrenaud X, Palecek T, Bultas J, Burnier M, Hayoz D. Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease. Acta Paediatr Suppl. 2006;95:63-68.
7. Elleder M. Sequelae of storage in Fabry disease: pathology and comparison with other lysosomal storage diseases. Acta Paediatr Suppl. 2003;92:46-53.
8. Blanco J, Herrero J, Arias LF, Garcia-Miralles N, Gamez C, Barrientos A. Renal variant of Anderson-Fabry disease and bilateral renal cell carcinoma. Pathol Res Pract. 2005;200:857-860.
9. Rosenthal D, Lien YH, Lager D, Lai LW, Shang S, Leung N, Fervenza FC. A novel α-galactosidase a mutant (M42L) identifed in a renal variant of Fabry disease. Am J Kidney Dis. 2004;44:e85-e89.
10. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, Yoshida A, Kuriyama M, Hayashibe H, Sakuraba H. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med. 1995;333:288-293.
11. von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG, Christomanou H, Kandolf R, Bishop DF, Desnick RJ. An atypical variant of Fabry's disease with manifestations confned to the myocardium. N Engl J Med. 1991;324:395-399.
12. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ. Safety and effcacy of recombinant human α-galactosidase A: replacement therapy in Fabry's disease. N Engl J Med. 2001;345:9-16.
13. Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285:2743-2749.
14. Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta AB. Effects of enzyme replacement therapy on the cardiomyopa-thy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart. 2008;94:153-158.
15. Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, Aerts JM, Hirth A, Hollak CE. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or βat a dose of 0.2 mg/kg. PLoS One. 2007;2:e598.
16. Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C. Clinical beneft of enzyme replacement therapy in Fabry disease. Kidney Int. 2006;69:1216-1221.
17. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ. Agalsidase-β therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007;146:77-86.
18. Kampmann C, Linhart A, Devereux RB, Schiffmann R. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12-to 36-month, retrospective, blinded echocardio-graphic pooled analysis. Clin Ther. 2009;31:1966-1976.
19. Rombach SM, Twickler TB, Aerts JM, Linthorst GE, Wijburg FA, Hollak CE. Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab. 2010;99:99-108.
20. Moore DF, Kaneski CR, Askari H, Schiffmann R. The cerebral vasculopa-thy of Fabry disease. J Neurol Sci. 2007;257:258-263.
21. DeGraba T, Azhar S, Dignat-George F, Brown E, Boutiere B, Altarescu G, McCarron R, Schiffmann R. Profle of endothelial and leukocyte activation in Fabry patients. Ann Neurol. 2000;47:229-233.
22. Moore DF, Ye F, Brennan ML, Gupta S, Barshop BA, Steiner RD, Rhead WJ, Brady RO, Hazen SL, Schiffmann R. Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study. J Magn Reson Imaging. 2004;20:674-683.
23. Boutouyrie P, Laurent S, Laloux B, Lidove O, Grunfeld JP, Germain DP. Non-invasive evaluation of arterial involvement in patients affected with Fabry disease. J Med Genet. 2001;38:629-631.
24. Kalliokoski RJ, Kalliokoski KK, Penttinen M, Kantola I, Leino A, Viikari JS, Simell O, Nuutila P, Raitakari OT. Structural and functional changes in peripheral vasculature of Fabry patients. J Inherit Metab Dis. 2006;29:660-666.
25. Collin C, Briet M, Tran TC, Beaussier H, Benistan K, Bensalah M, Mousseaux E, Froissart M, Bozec E, Laurent S, Boutouyrie P, Germain DP. Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease. Eur J Cardiovasc Prev Rehabil. 2012;19:43-54.
26. Gerrits EG, Lutgers HL, Kleefstra N, Graaff R, Groenier KH, Smit AJ, Gans RO, Bilo HJ. Skin autofuorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care. 2008;31:517-521.
27. Hartog JW, de Vries AP, Lutgers HL, Meerwaldt R, Huisman RM, van Son WJ, de Jong PE, Smit AJ. Accumulation of advanced glycation end products, measured as skin autofuorescence, in renal disease. Ann N Y Acad Sci. 2005;1043:299-307.
28. Tanaka K, Tani Y, Asai J, Nemoto F, Kusano Y, Suzuki H, Hayashi Y, Asahi K, Katoh T, Miyata T, Watanabe T. Skin autofuorescence is associated with renal function and cardiovascular diseases in pre-dialysis chronic kidney disease patients. Nephrol Dial Transplant. 2011;26:214-220.
29. Lutgers HL, Graaff R, de VR, Smit AJ, Dullaart RP. Carotid artery intima media thickness associates with skin autofuoresence in non-diabetic subjects without clinically manifest cardiovascular disease. Eur J Clin Invest. 2010;40:812-817.
30. Barbey F, Brakch N, Linhart A, Rosenblatt-Velin N, Jeanrenaud X, Qanadli S, Steinmann B, Burnier M, Palecek T, Bultas J, Hayoz D. Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler Thromb Vasc Biol. 2006;26:839-844.
31. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van RC, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A. 2008;105:2812-2817.
32. Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, Kuiper S, Vd Bergh Weerman MA, Groener JE, Poorthuis BJ, Hollak CE, Aerts JM. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta. 2010;1802:741-748.
33. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van LF. Using standardized serum creatinine values in the modifcation of diet in renal disease study equation for estimating glo-merular fltration rate. Ann Intern Med. 2006;145:247-254.
34. Devereux RB, Koren MJ, de Simone G, Roman MJ, Laragh JH. Left ventricular mass as a measure of preclinical hypertensive disease. Am J Hypertens. 1992;5:175S-181S.
35. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfeld J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R. Guidelines for the ultrasound assessment of endothelial-dependent fow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257-265.
36. Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, Thorpe SR, Baynes JW, Gans RO, Smit AJ. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia. 2004;47:1324-1330.
37. Puccio D, Coppola G, Corrado E, Muratori I, Pistone G, Buongiorno MR, Arico M, Novo S. Noninvasive evaluation of endothelial function in patients with Anderson-Fabry disease. Int Angiol. 2005;24:295-299.
38. Juonala M, Viikari JS, Laitinen T, Marniemi J, Helenius H, Ronnemaa T, Raitakari OT. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the cardiovascular risk in young Finns Study. Circulation. 2004;110:2918-2923.
39. Kobayashi K, Akishita M, Yu W, Hashimoto M, Ohni M, Toba K. Interrelationship between non-invasive measurements of atherosclerosis: fow-mediated dilation of brachial artery, carotid intima-media thickness and pulse wave velocity. Atherosclerosis. 2004;173:13-18.
40. de Groot E, van Leuven SI, Duivenvoorden R, Meuwese MC, Akdim F, Bots ML, Kastelein JJ. Measurement of carotid intima-media thickness to assess progression and regression of atherosclerosis. Nat Clin Pract Cardiovasc Med. 2008;5:280-288.
41. Takao M, Mori T, Orikasa H, Oh H, Suzuki K, Koto A, Yamazaki K. Postmortem diagnosis of Fabry disease with acromegaly and a unique vasculopathy. Virchows Arch. 2007;451:721-727.
42. Chimenti C, Morgante E, Critelli G, Russo MA, Frustaci A. Coronary artery bypass grafting for Fabry's disease: veins more suitable than arteries? Hum Pathol. 2007;38:1864-1867.
43. Fisher EA, Desnick RJ, Gordon RE, Eng CM, Griepp R, Goldman ME. Fabry disease: an unusual cause of severe coronary disease in a young man. Ann Intern Med. 1992;117:221-223.
44. Chambless LE, Folsom AR, Clegg LX, Sharrett AR, Shahar E, Nieto FJ, Rosamond WD, Evans G. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol. 2000;151:478-487.
45. de Cavanagh EM, Ferder M, Inserra F, Ferder L. Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint. Am J Physiol Heart Circ Physiol. 2009;296:H550-H558.
46. Batista EC, Carvalho LR, Casarini DE, Carmona AK, dos Santos EL, da Silva ED, dos Santos RA, Nakaie CR, Rojas MV, de Oliveira SM, Bader M, D'Almeida V, Martins AM, de Picoly SK, Pesquero JB. ACE activity is modulated by the enzyme α-galactosidase A. J Mol Med (Berl). 2011;89:65-74.
47. Brakch N, Dormond O, Bekri S, Golshayan D, Correvon M, Mazzolai L, Steinmann B, Barbey F. Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. Eur Heart J. 2010;31:67-76.
48. Hla T. Physiological and pathological actions of sphingosine 1-phosphate. Semin Cell Dev Biol. 2004;15:513-520.
49. Hla T, Venkataraman K, Michaud J. The vascular S1P gradient-cellular sources and biological signifcance. Biochim Biophys Acta. 2008;1781:477-482.
50. Smid BE, Rombach SM, Aerts JM, Kuiper S, Mirzaian M, Overkleeft HS, Poorthuis BJ, Hollak CE, Groener JE, Linthorst GE. Consequences of a global enzyme shortage of agalsidase βin adult Dutch Fabry patients. Orphanet J Rare Dis. 2011;6:69.